Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03761108 · ClinicalTrials.gov registry record · Phase 1

Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

A Phase 1 study of Multiple Myeloma, sponsored by Regeneron Pharmaceuticals.

Recruiting
Registry status
Phase 1
Development phase
387
Enrollment target
20
Study locations

NCT03761108 is a Phase 1 study of Multiple Myeloma that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 387 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (29% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03761108, a Phase 1 study of Multiple Myeloma, is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.

RECRUITING
Registry status
Phase 1
Development phase
387 participants
Enrollment target
20
Study locations

Study Summary

The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs that linvoseltamab can effectively treat cancer. The study is looking at several other research questions, including: * Side effects that may be experienced by people receiving linvoseltamab * How linvoseltamab works in the body * How much linvoseltamab is present in the blood * How linvoseltamab may work to treat cancer

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Linvoseltamab

Study Locations (20)

Other

  • ZNA Psychiatrisch Ziekenhuis Stuivenberg - Antwerp
  • Cliniques Universitaires Saint-Luc - Brussels
  • Universitatsklinikum Wurzburg - Würzburg

Florida

  • Sylvester Comprehensive Cancer Center - Miami
  • Moffitt Cancer Center - McKinley Drive - Tampa

Michigan

  • C. S. Mott_University of Michigan - Ann Arbor
  • Barbara Ann Karmanos Cancer Center - Detroit

New York

  • Icahn School of Medicine at Mount Sinai - New York
  • Columbia University Medical Center - New York

Georgia

  • Emory University Hospital - Atlanta

Indiana

  • Indiana University_Michigan Street - Indianapolis

Kentucky

  • Norton Cancer Institute - Louisville

New Jersey

  • Rutgers Cancer Institute of New Jersey - New Brunswick

Trial Details

FieldValue
Enrollment Target 387 participants
Start Date 2019-01-23
Est. Completion 2033-06-16
Phase Phase 1

Sponsor

Regeneron Pharmaceuticals

280 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03761108

The ClinicalTrials.gov registry entry for NCT03761108 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 387 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (29% lower). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Linvoseltamab is the first listed.

NCT03761108 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Other, Florida, Michigan.

Frequently Asked Questions

What is clinical trial NCT03761108 about?

NCT03761108 is a clinical study titled "Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma". The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs that linvoseltamab can effectively treat cancer. The study is looking at several other research que...

What is the current status of trial NCT03761108?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 387 participants. The study started on 2019-01-23. Estimated completion is 2033-06-16.

What conditions does trial NCT03761108 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT03761108?

The interventions under investigation include: Linvoseltamab (DRUG).

Who is sponsoring clinical trial NCT03761108?

This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03761108 being conducted?

This trial has 20 study locations across Florida, Georgia, Indiana, Kentucky, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.